239 related articles for article (PubMed ID: 19243595)
1. Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors.
Abdulamir AS; Hafidh RR; Kadhim HS; Abubakar F
J Exp Clin Cancer Res; 2009 Feb; 28(1):27. PubMed ID: 19243595
[TBL] [Abstract][Full Text] [Related]
2. Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous cell carcinoma of urinary bladder.
Chaudhary KS; Lu QL; Abel PD; Khandan-Nia N; Shoma AM; el Baz M; Stamp GW; Lalani EN
Br J Urol; 1997 Jan; 79(1):78-84. PubMed ID: 9043502
[TBL] [Abstract][Full Text] [Related]
3. Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1).
Badr KM; Nolen JD; Derose PB; Cohen C
Hum Pathol; 2004 Feb; 35(2):184-9. PubMed ID: 14991535
[TBL] [Abstract][Full Text] [Related]
4. DNA copy number changes in Schistosoma-associated and non-Schistosoma-associated bladder cancer.
El-Rifai W; Kamel D; Larramendy ML; Shoman S; Gad Y; Baithun S; El-Awady M; Eissa S; Khaled H; Soloneski S; Sheaff M; Knuutila S
Am J Pathol; 2000 Mar; 156(3):871-8. PubMed ID: 10702404
[TBL] [Abstract][Full Text] [Related]
5. TGF-B1 pathway as biological marker of bladder carcinoma schistosomal and non-schistosomal.
Shaker O; Hammam O; Wishahi M; Roshdi M
Urol Oncol; 2013 Apr; 31(3):372-8. PubMed ID: 21429769
[TBL] [Abstract][Full Text] [Related]
6. P53 and cancer-associated sialylated glycans are surrogate markers of cancerization of the bladder associated with Schistosoma haematobium infection.
Santos J; Fernandes E; Ferreira JA; Lima L; Tavares A; Peixoto A; Parreira B; Correia da Costa JM; Brindley PJ; Lopes C; Santos LL
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3329. PubMed ID: 25502795
[TBL] [Abstract][Full Text] [Related]
7. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours.
Warren W; Biggs PJ; el-Baz M; Ghoneim MA; Stratton MR; Venitt S
Carcinogenesis; 1995 May; 16(5):1181-9. PubMed ID: 7767983
[TBL] [Abstract][Full Text] [Related]
9. Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer.
Hammam OA; Aziz AA; Roshdy MS; Abdel Hadi AM
Medscape J Med; 2008 Mar; 10(3):60. PubMed ID: 18449376
[TBL] [Abstract][Full Text] [Related]
10. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2.
Vollmer RT; Humphrey PA; Swanson PE; Wick MR; Hudson ML
Cancer; 1998 Feb; 82(4):715-23. PubMed ID: 9477105
[TBL] [Abstract][Full Text] [Related]
11. Elevated oxidative stress and DNA damage and repair levels in urinary bladder carcinomas associated with schistosomiasis.
Salim EI; Morimura K; Menesi A; El-Lity M; Fukushima S; Wanibuchi H
Int J Cancer; 2008 Aug; 123(3):601-8. PubMed ID: 18478569
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
14. Human papilloma virus and p53 expression in bladder cancer in Egypt: relationship to schistosomiasis and clinicopathologic factors.
Helal Tel A; Fadel MT; El-Sayed NK
Pathol Oncol Res; 2006; 12(3):173-8. PubMed ID: 16998598
[TBL] [Abstract][Full Text] [Related]
15. p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions.
Kamel D; Soini Y; Nuorva K; Khalifa A; Mangoud A; Vähäkangas K; Pääkkö P
Virchows Arch; 1994; 424(4):349-55. PubMed ID: 7911381
[TBL] [Abstract][Full Text] [Related]
16. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
17. Molecular events underlying schistosomiasis-related bladder cancer.
Ramchurren N; Cooper K; Summerhayes IC
Int J Cancer; 1995 Jul; 62(3):237-44. PubMed ID: 7628866
[TBL] [Abstract][Full Text] [Related]
18. Deletions of p15 and p16 in schistosomal bladder cancer correlate with transforming growth factor-alpha expression.
Swellam M; El-Aal AA; AbuGabel KM
Clin Biochem; 2004 Dec; 37(12):1098-104. PubMed ID: 15589816
[TBL] [Abstract][Full Text] [Related]
19. Possible role of telomerase and sFas in pathogenesis of various bladder lesions associated with schistosomiasis.
Shaker OG; Hammam O; Salehd A; el-Leithy T; Wishahi M
Clin Biochem; 2009 Jun; 42(9):864-72. PubMed ID: 19272297
[TBL] [Abstract][Full Text] [Related]
20. Clinical presentation and outcome of bladder schistosoma-unrelated squamous cell carcinoma: report on 33 consecutive cases.
Riadh BS; El Atat R; Sfaxi M; Derouiche A; Kourda N; Chebil M
Clin Genitourin Cancer; 2007 Sep; 5(6):409-12. PubMed ID: 17956717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
